TIMOČKI MEDICINSKI GLASNIK

Pregledni članak Vol. 47 (2022) br. 4

UDK 616-008.9-056.7
616.43-056.7
COBISS.SR-ID 109152777

ZNAČAJ NOVOROĐENAČKOG SKRININGA U PREVENCIJI RETKIH METABOLIČKO-ENDOKRINOLOŠKIH POREMEĆAJA

Mirka Knežević (1), Gordana Magdelinić (2), Milena Magdelinić (3), Milan Magdelinić (4), Anja Mijušković (5)

(1,2) OPŠTA BOLNICA BERANE, BERANE, CRNA GORA; (3) KLINIČKI CENTAR CRNE GORE, PODGORICA, CRNA GORA; (4,5) DOM ZDRAVLJA ANDRIJEVICA, ANDRIJEVICA, CRNA GORA

SAŽETAK: Ukazujući na značaj rane dijagnoze i lečenja bolesti u najranijoj životnoj dobi novorođenački skrining je uvršten u obavezni vid zdravstvene zaštite dece i sprovodi se u zemljama širom sveta. Novorođenački skrining obuhvata teške nasledne metaboličke i endokrinološke bolesti, koje se klinički odmah ne manifestuju dok u kasnijem toku dovode do ometenosti u rastu i razvoju sa visokim procentom fizičkog i psihičkog invaliditeta. Rano dijagnostikovana bolest omogućava brzi terapijski pristup kako bolest ne bi napredovala i adekvatan rast i razvoj deteta. Cilj skrininga novorođenčadi je rano otkrivanje bolesti novorođenčeta kod koje će rana dijagnostika i lečenje dovesti do značajnog smanjenja smrtnosti, morbiditeta i invaliditeta. Cilj ovoga rada je da se prikažu neka od najčešćih metaboličkih i endokrinoloških oboljenja koja su uvrštena u program novorođenačkog skriniga u Crnoj Gori i zemaljama u okruženju, kao i upoznavanje sa komplikacijama blagovremeno nedijagnostikovanog oboljenja, terapijskim mogućnostima i prognozom bolesti nakon blagovremeno započete terapije.

Ključne reči: Novorođenački skrining, nasledne bolesti, endokrinološki poremećaji, metabolički poremaćaji

UVOD

Pre više od četiri decenije mnoge zemlje su pokrenule programe neonatalnog skrininga u cilju otkrivanja novorođenčadi sa naslednim metaboličkim i endokrinološkim oboljenjima za koja bi rana dijagnostika i lečenje sprečila ozbiljne i trajne poremećaje zdravlja. Fenilketonurija je u mnogim zemljama bila prvi poremećaj uvršten u novorođenački skrining. U decenijama nakon toga program se širio postepeno, i obuhvatao sve veći broj teških poremećaja koji za posledicu imaju visok stepen fizičkog i intelektualnog invaliditeta.

Svetska zdravstvena organizacija definiše ulogu skrininga kao otkrivanje bolesti koja se može lečiti, sa adekvatno shvaćenom prirodnom istorijom, u asimptomatskoj fazi, kako bi se započelo lečenje i sprečili simptomi ili da bi se odložile komplikacije. Skrininig novorođenčeta se počeo primenjivati 1960. godine radom američkog mikrobiologa Dr Roberta Gatrija (Robert Guthrie). Prva interncionalna diskusija o skriningu novorođenčeta pod organizacijom Svetske zdravstvene organizacije održana je 1967. godine kada je grupa naučnika za kongenitalne poremećaje metabolizma raspravljala o tehničkim i etičkim aspektima skrininga.

Gatrijev test (Guthrie test) je obavezna mera zdravstvene zaštite i radi se svakom novorođenčetu, bilo da je ono zdravo ili bolesno, rođeno u ili pre termina. Ova laboratorijska analiza se uglavnom izvodi već u porodilištu, najčešće od 48 do 72 sata od rođenja novorođenčeta, mada može da se radi i do 8. dana života novorđenčeta. Važećem preporukom Savetodavnog komiteta za nasledne bolesti kod novorođenčadi i dece, čija aktuelna verzija datira iz 2016. godine u SAD je definisan "preporučeni univerzalni skrinig panel" koji se sastoji od osnovnog spiska od 34 oboljenja i proširenog spiska na kojem se nalazi jos 26 bolesti. Oboljenja za koja se preporučuju skrining mogu se klasifikovati na nekoliko grupa: poremećaje metabolizma organskih kiselina, poremećaj oksidacije masnih kiselina, poremećaje metabolizma aminokiselina, endokrine poremećaje i hemoglobinopatije. Od endokrinih poremećaja skrining se preporučuje na kongenitalni hipotireoidizam i kongenitalnu adrenalnu hiperplaziju i to u okviru osnovnog panela [1]. Lista bolesti koje će obuhvatiti skrining test, zavisi od zdravstvenog sistema države i njenog skrining programa. Koja će se bolest proveravati najviše zavisi od njene učestalosti, od dostupnosti terapije ali i od toga koliko je zemlja razvijena i ima li sredstva da plati skrining za svu novorođenčad.

U Crnoj Gori od 2007. godine kao obavezni vid zdravstvene zaštite novorođenčeta

Adresa autora: Mirka Knežević, OPŠTA BOLNICA BERANE, BERANE, CRNA GORA
E-mail: mirkaknezevic610@gmail.com
Rad primljen: 08.11.2022. Rad prihvaćen: 18.01.2023. Elektronska verzija objavljena: 24.02.2023.

THE IMPORTANCE OF NEWBORN SCREENING IN THE PREVENTION OF RARE METABOLIC-ENDOCRINOLOGICAL DISORDERS

Mirka Knežević (1), Gordana Magdelinić (2), Milena Magdelinić (3), Milan Magdelinić (4), Anja Mijušković (5)

(1,2) BERANE GENERAL HOSPITAL, BERANE, MONTENEGRO; (3) CLINICAL CENTER OF MONTENEGRO, PODGORICA, MONTENEGRO; (4,5) ANDRIJEVICA HEALTH CENTER, ANDRIJEVICA, MONTENEGRO

ABSTRACT: Indicating the importance of early diagnosis and treatment of diseases at the earliest age of life, newborn screening is included in the mandatory form of health care for children and is carried out in countries around the world. Newborn screening includes severe hereditary metabolic and endocrinological diseases, which do not immediately manifest themselves clinically, while in the later course they lead to impaired growth and development with a high percentage of physical and psychological disability. An early diagnosed disease enables a quick therapeutic approach so that the disease does not progress, and adequate growth and development of the child. The goal of newborn screening is the early detection of newborn diseases where early diagnosis and treatment will lead to a significant reduction in mortality, morbidity and disability. The aim of this work is to present some of the most common metabolic and endocrinological diseases that are included in the newborn screening program in Montenegro and the surrounding countries, as well as to familiarize with the complications of undiagnosed diseases in a timely manner, therapeutic possibilities and the prognosis of the disease after timely treatment.

Key words: Newborn screening, hereditary diseases, endocrinological disorders

INTRODUCTION

More than four decades ago, many countries initiated neonatal screening programs in order to identify newborns with inherited metabolic and endocrinological diseases for which early diagnosis and treatment would prevent serious and permanent health disorders. Phenylketonuria was the first disorder included in newborn screening in many countries. In the decades after that, the program expanded gradually, and included an increasing number of severe disorders that result in a high degree of physical and intellectual disability.

The World Health Organization defines the role of screening as the detection of a treatable disease, with an adequately understood natural history, in the asymptomatic phase, in order to initiate treatment and prevent symptoms or to delay complications. Newborn screening began to be applied in 1960 with the work of the American microbiologist Dr. Robert Guthrie. The first international discussion on newborn screening organized by the World Health Organization was held in 1967 when a group of scientists on congenital metabolic disorders discussed the technical and ethical aspects of screening.

Guthrie's test is a mandatory health care measure and is performed on every newborn, whether healthy or sick, born on or before the due date. This laboratory analysis is usually performed already in the maternity ward, most often in the first 48 hours after the baby's birth, although it can be done up to the 8th day of the baby's life. The current recommendation of the Advisory Committee on Inherited Diseases in Infants and Children, the current version of which dates from 2016 in the USA, defines a "recommended universal screening panel" consisting of a basic list of 34 diseases and an expanded list that includes 26 more diseases. Diseases for which screening is recommended can be classified into several groups: organic acid metabolism disorders, fatty acid oxidation disorders, amino acid metabolism disorders, endocrine disorders and hemoglobinopathies. From endocrine disorders, screening is recommended for congenital hypothyroidism and congenital adrenal hypoplasia within the basic panel [1]. The list of diseases that will be covered by the screening test depends on the health system of the country and its screening program. Which disease will be checked mostly depends on its frequency, on the availability of

uveden je neonatalni skrining na hipotireozu, i jedina je bolest iz grupe naslednih endokrinoloških oboljenja koju skrining obuhvata. Od zemalja u okruženju, Slovenija ima najbolji skrinig program gde je pored hipotireoze i fenilketonurije uvršteno još sedamnaest oboljenja. Hrvatska ima skrining program koji obuhvata osam bolesti: fenilketonuriju, hipotireozu, tri poremećaja razgradnje masnih kiselina, glutarnu aciduriju tipa 1, izovalerićnu acidemiju, nedostatak karnitina.

Novorođenački skrining na fenilketonuriju

Skrining na fenilketonuriju je preduslov za ranu primenu dijete, koja je neophodna za prevenciju teških neuroloških poremećaja kod dece sa dijagnostkovanim oboljenjem.

Fenilketonurija je najčešći urođeni metabolički poremećaj koji uzrokuje težak stepen fizičkog i pshičkog invaliditeta ukoliko se blagovremeno ne dijagnostikuje i ne započne terapijski tretman. Fenilketonurija je bolest koja se može lečiti i navedena je u nacionalnom programu skrininga novorođenčadi u zemljama širom sveta. Novorođenčad sa pozitivnim indikacijama skrininga mogu postići zadovoljavajući terapijski efekat blagovremenom kontrolom unosa fenilalanina nakon postavljanja dijagnoze. Kombinacija rane dijagnoze i početka lečenja rezultira normalim telesnim i intelektualnim razvojem za većinu dece sa fenilketonurijom.

Fenilketonurija i druge hiperfenilalaninemije su skupina naslednih poremećaja koje nastaju zbog poremećaja u oksidaciji aminokiseline fenilalanin u tirozin [2]. Fenilketonuriji pripada posebno mesto među naslednim metaboličkim bolestima. To je prva bolest iz te skupine u kojoj je jasno utvrđena veza između naslednog biohemijskog poremećaja i mentalne zaostalosti (Asbjorn Fölling 1934.), prva bolest iz te kategorije za koju je otkrivena mogućnost lečenja dijetom (Horst Bickel 1954.) i prva za koju je izrađen labaratorijski test koji se upotrebljava u skriningu novorođenčadi u celokupnoj novorođenačkoj populaciji (Robert Guthrie 1963) [3]. Prevalenca fenilketonurije u svetu se kreće oko 1: 10 000 novorođenčadi [4].

Fenilalanin je esencijalna aminokiselina, od koje se nakon resorpcije iz creva manja količina ugrađuje u telesne proteine, a preostali, veći deo mora se uz pomoć enzima fenilalanin-hidroksilaze u jetri oksidirati u tirozin. Uzrok fenilketonurije su mutacije gena koji se nalazi na hromozomu 12 koji kodira jetreni enzim fenilalanin-hidroksilazu. Posledica je insuficijencija enzima i nemogućnost oksidacije fenilalanina u tirozin sa povećanjem koncentracije fenilalanina i njegovih "nenormalnih "metabolita u ćelijama i telesnim tečnostima. Danas još nije poznat mehanizam kojim fenilalanin ili njegovi metaboliti u velikim koncentacijama oštećuju funkciju mozga, ali je činjenica da njihovo održavanje u normalnim granicama kod dece sa fenilketonurijom odgovarajućim dijetalnim režimom sprečava oštećenje mozga [5].

Deca sa klasičnom fenilketonurijom u prvim danima i nedeljama života nemaju uočljivih simptoma. Tek nakon nekoliko nedelja javlju se znaci usporenog psihomotornog razvoja, deca ne nauče hodati, sedeti u pravo vreme, 25 % dece ima epileptičke napade, razvija se hipotonija muskulature, psihomotorni nemir, promene ponašanja, mikrocefalija, zaostatak u telesnom razvoju. Oko četvrtine zahvaćene dece ima dojenački ekcem, hipopigmentaciju kože i kose, miris znoja i mokraće na miševe što potiče od fenilmlečne kiseline koju ta deca izlučuju. Već tokom prve godine dolazi do teške mentalne retardacije (IQ 30) [6].

Slika 1. Dete sa fenilketonurijom

Izvor: https://img.medscapestatic.com/pi/meds/ckb/07/44107tn.jpg



therapy, but also on how developed the country is and whether it has the means to pay for screening for all newborns.

Neonatal screening for hypothyroidism has been introduced in Montenegro since 2008 as a mandatory form of health care for newborns, and it is the only disease from the group of hereditary endocrinological diseases that screening includes.

Screening for phenylketonuria

Screening for phenylketonuria is a prerequisite for the early application of a restricted diet, which is necessary for the prevention of severe neurological disorders in children diagnosed with the disease. Phenylketonuria is the most common congenital metabolic disorder that causes a severe degree of physical and mental disability if it is not diagnosed in a timely manner and therapeutic treatment is not started. Phenylketonuria is a treatable disease and is listed in the national newborn screening program in countries around the world. Newborns with positive screening indications can achieve a satisfactory therapeutic effect by timely control of phenylalanine intake after diagnosis. The combination of early diagnosis and initiation of treatment results in normal physical and intellectual development for most children with phenylketonuria. Phenylketonuria and other hyperphenylalaninemia are a group of hereditary disorders that arise due to disorders in the oxidation of the amino acid phenylalanine to tyrosine [2]. Phenylketonuria has a special place among hereditary metabolic diseases. It is the first disease from that group in which the link between a hereditary biochemical disorder and mental retardation was clearly established (Følling 1934), the first disease from that category for which the possibility of dietary treatment was discovered (Bickel 1954) and the first for which a laboratory test was developed a test used in newborn screening in the entire newborn population (Guthrie 1963) [3]. The prevalence of phenylketonuria in the world is around 1: 10.000 newborns [4].

Phenylalanine is an essential amino acid, of which, after resorption from the intestines, a smaller amount is incorporated into body proteins, and the remaining, larger part must be oxidized into tyrosine with the help of the enzyme phenylalanine-hydroxylase in the liver. Phenylketonuria is caused by mutations in the gene encoding the liver enzyme phenylalanine hydroxylase. The consequence is enzyme insufficiency and the inability to oxidize phenylalanine to tyrosine with an increase in the concentration of phenylalanine and its "abnormal" metabolites in cells and body fluids. Today, the mechanism by which phenylalanine or its metabolites in high concentrations damage brain function is not yet known, but it is a fact that maintaining them within normal limits in phenylketonuric children with an appropriate dietary regimen prevents brain damage [5]..

Figure 1. A child with phenylketonuria
https://img.medscapestatic.com/pi/meds/ckb/07/44107tn.jpg



Children with classic phenylketonuria have no noticeable symptoms in the first days and weeks of life. It is only after a few weeks that signs of slowed psychomotor development appear, children do not learn to walk, sit at the right time, 25% of children have epileptic

TIMOČKI MEDICINSKI GLASNIK

Pregledni članak Vol. 47 (2022) br. 4

Kako se kod svakog novorođenčeta radi skrinig na fenilketonuriju (Guthrie test), u dece sa pozitivnim Guthrie skrinig testom određuje se se koncentracija fenil-alanina i tirozina u krvi. Na osnovu vrednosti fenilalanina u krvi, bolest se klasifikuje kao blaga hiperfenilalaninemija: 120–360 mmol; blaga siva zona 360–600 mmol; blagi oblik fenilketonurije: 600–900 mmol; umereni: 900–1200 mmol i klasični >1.200 mmol [7].

Lečenje fenilketonurije se sprovodi doživotnim ograničenjem unosa fenil-alanina do količine neophodne za izgradnju vlastitih proteina od rođenja. U odojčadi se isključivo koriste mlečne formule sa malo fenil-alanina. Primena dijete ima trostruki cilj:

1. Sprečva se akumulacija prekomerne količine fenilalanina u krvi (a samim tim i u mozgu) strogom kontrolom prirodnog unosa proteina/fenilalanina.

2. Zamena prirodnog proteina koji je uklonjen iz ishrane bezbednim proteinom ili proteinom bez fenilalanina, koji se naziva sintetički protein, smeša/suplement aminokiselina ili zamena za proteine. Sve zamene za proteine su bez fenilalanina ili imaju veoma malo fenilalanina.

3. Postizanje normalnog rasta i statusa uhranjenosti. Ovo se postiže osiguravanjem da ishrana sadrži izbalansiran unos svih hranljivih materija i energije. Suplementi vitamina i minerala se ili dodaju zameni proteina ili daju kao poseban dodatak.

U ishrani se doživotno ograničava unos namirnica koje obiluju fenilalaninom: mleko, mlečni proizvodi, meso, riba, piletina, jaja, pasulj, orasi. U ishrani se preporučuje unos voća, povrća, žitarica [8].

Prognoza nelečene fenilketonurije je loša sa obzirom na propadanje mentalnih i nervnih funkcija, propratnu simptomatsku epilepsiju i teškoće i komplikacije koje prete takovom detetu. Oko polovine nelečene dece doživi 20 godina, oko trećine 30 godina. Uz blagovremenu dijagnostiku u najranijoj dobi i adekvatnu ishranu deca sa lečenom fenilketonurijom se ne razlikuju od zdravih vršnjaka.

Prevencija fenilketonuričnе embriopatije započinje pre rađanja deteta, kada gravidna žena koja ima fenilketonuriju sprovodi dijetu bez fenilalanina. Ako pre koncepcije i u toku trudnoće dijeta nije stroga doći će do oštećenja centralnog nervnog sistema fetusa, urođenih srčanih mana i mikrocefalije. Po rođenju novorođenčetu se radi Gatrijev test (Guthrie test).

Uzorak treba uzeti svakom zdravom, bolesnom, donešenom i nedonešenom novorođenčetu. Tačan period za uzimanje uzoraka ne bi trebalo da bude kraći od 48 sati hranjenja proteinima i ne bi trebalo da prelazi 30 dana od rođenja; međutim, idealan period bi bio između trećeg i sedmog dana rođenja kod novorođenčadi [9].

Budući da antibiotska terapija može test na fenilketonuriju učiniti lažno negativnim uzorak se uzima u načelu nakon završetka antibiotske terapije. Najsigurnije mesto za uzimanje uzorka krvi je dorzalna strana pete novorođenčeta. Označeni krug mora biti u potpunosti ispunjen krvlju, ne smeta ukoliko je krv prešla rubove kruga. Pre uboda deteta treba sačekati da se da se dezinfekciono sredstvo kojim je koža obrisana potpuno osuši. U suprotnom sa uzorkom krvi se meša dezinfekciono sredstvo te je takav uzorka neupotrebljiv. Jod i sredstva koja sadrže jod se ne upotrebljavaju jer ometaju određivanje tireotropina za dijagnostikovanje kongenitalne hipotireoze. Na poleđini papira važno je napisati da li dete uzima antibiotike i je li teško bolesno.

Novorođenački skrinig na hipotireozu

Kongenitalna hipotireoza može se dijagnostikovati kasno ili može proći potpuno nedijagnostikovano, izazivajući poremećaje zdravlja deteta, ekonomski i socijalni teret za porodicu. Terapijski tretman dijagnostikovane kongenitalne hipotireoza je jednostavan, jeftin i efikasan. Sa ranom dijagnozom i terapijom novorođenče se razvija normalno bez mentalnog hendikepa i postaje produktivan član društva. Patnja deteta, postojanje ekonomskog i socijalnog tereta uzrokovanih kongenitalnom hipotireozom, obavezala je institucije mnogih zemalja da novorođenački skrining na hipotireozu uvrste u obavezan vid zdravstvene zaštite deteta.

U Crnoj Gori, kao obavezan vid zdravstvene zaštite djeteta uveden je skrining na hipotireozu 2007. godine. Do danas, kongenitalna hipotireoza je jedino endokrino oboljenje obuhvaćeno skrining programom novorođenčadi.

Glavne kliničke karakteristike nelečene kongenitalne hipotireoze su poremećaj rasta i odloženi neurokognitivni razvoj koji rezultira mentalniom retardacijom.

seizures, develop hypotonia of muscles, psychomotor restlessness, behavioral changes, microcephaly, lag in physical development. About a quarter of the affected children have infantile eczema, hypopigmentation of the skin and hair, and a mouse-like smell of sweat and urine. Severe mental retardation occurs already during the first year (IQ 30) [6].

As every newborn is screened for phenylketonuria (Guthrie's test), the concentration of phenylalanine and tyrosine in the blood is determined in children with a positive Guthrie screening test. Based on the value of phenylalanine in the blood, the disease is classified as mild hyperphenylalaninemia: 120–360 mmol; light gray zone 360–600 mmol; mild form of phenylketonuria: 600–900 mmol; moderate: 900–1200 mmol and classical>1,200 mmol [7].

Treatment of phenylketonuria is carried out by lifelong restriction of phenylalanine intake to the amount necessary for the construction of own proteins from birth. In infants, milk formulas with little phenylalanine are exclusively used. The implementation of the diet has a threefold goal:

1. The accumulation of an excessive amount of phenylalanine in the blood (and therefore in the brain) is prevented by strict control of the natural protein/phenylalanine intake.

2.Replacing natural protein that has been removed from the diet with a safe or phenylalanine-free protein, called a synthetic protein, amino acid blend/supplement, or protein replacement. All protein replacements are phenylalanine-free or very low in phenylalanine.

3. Achieving normal growth and nutritional status. This is achieved by ensuring that the diet contains a balanced intake of all nutrients and energy. Vitamin and mineral supplements are either added to protein replacement or given as a separate supplement.

In the diet, the intake of foods rich in phenylalanine is restricted for life: milk, dairy products, meat, fish, chicken, eggs, beans, nuts. The intake of fruits, vegetables and cereals is recommended in the diet [8].

The prognosis of untreated phenylketonuria is poor considering the deterioration of mental and nervous functions, the accompanying symptomatic epilepsy and the difficulties and complications that threaten such a child. About half of untreated children live to be 20 years old, and about a third live to be 30 years old. With timely diagnosis at an early age and adequate dietary nutrition, children with treated phenylketonuria do not differ from healthy peers.

Prevention begins before the birth of a child, when a pregnant woman with phenylketonuria implements a diet without phenylalanine. If the diet is not strict before conception and during pregnancy, damage to the central nervous system of the fetus, congenital heart defects and microcephaly will occur. After birth, the newborn is given a Guthrie test.

A sample should be taken from every healthy, sick, term and non-term newborn. The exact period for sampling should not be less than 48 hours of protein feeding and should not exceed 30 days from birth; however, the ideal period would be between the third and seventh day of birth in newborns [9].

Since antibiotic therapy can make the test for phenylketonuria falsely negative, the sample is generally taken after the antibiotic therapy has ended. The safest place to take a blood sample is the dorsal side of the newborn's heel. The marked circle must be completely filled.

with blood, it does not matter if the blood has crossed the edges of the circle. Before injecting the child, you should wait until the disinfectant used to wipe the skin is completely dry. Otherwise, a disinfectant is mixed with the blood sample, and such a sample is unusable. Iodine and means containing iodine are not used because they interfere with the determination of thyrotropin for diagnosing congenital hypothyroidism. It is important to write on the back of the paper whether the child is taking antibiotics and is seriously ill.

Screening for congenital hypothyroidism

Congenital hypothyroidism can be diagnosed late or go completely undiagnosed, causing health disorders for the child, economic and social burden for the family. Therapeutic treatment of diagnosed congenital hypothyroidism is simple, cheap and effective. With early diagnosis and therapy, the newborn develops normally without mental handicap and becomes a productive member of society. The child's suffering, the economic and social burden caused by congenital hypothyroidism, obliged the institutions of many countries to include

Širom sveta stopa incidence kongenitalne hipotireoze je 1: 2000-4000 novorođenčadi, dok za područja koja su deficitarna jodom beleže veću stopu incidencije [10].

Slika 2. Klinička slika kongenitalne hipotireoza

Izvor:https://www.researchgate.net/publication/44662677/figure/fig4/AS:279090520182836@1443551773718/Infant-with-congenital-hypothyroidism-A-3-month-old-infant-with-untreated-CH-picture_Q320.jpg



Kongenitalna hipotireoza se dijagnostikuje na rođenju pomoću Gatrijevog testa (Guthrie test). Ovaj test se bazira na merenju vrijednosti (TSH) tireostimulišućeg hormona ili (T4) tiroksina. Ako je nivo T4 u krvi iz uboda u petu nizak a povišen TSH rezultati skrininga ukazuju na postajanje kongenitalne hipotireoze. Potvrda dijagnoze se postavlja analizom hormona iz venske krvi gde se takođe meri nivo TSH i T4. Ako je vrednost T4 hormona niska, a vrednost TSH povišena dijagnoza je defiitivno potvrđena [11].

Cilj supstitucione hormonske terapije je dovesti dete u stanje eutireoze. Kod dijagnostifikovane kongenitalne hipotireoze terapija se započinje sa punom dozom hormona kako bi se sprečili ili umanjili štetni efekti hipotireoze na razvoj centralnog nervnog sistema. Preporučuje se održavanje T3 i T4 na gornjoj granici normale. Početkom terapije normalizuje se nivo T4 i T3 i dolazi do supresije povišenog TSH. Uz dobro vođenu terapiju postiže se normalan rast i gube se klinički znaci hipotireoze, ali prognoza mentalnog razvoja nije tako povoljna i zavisi pre svega od vremena kada je terapija započeta. Levotiroksin je hormonski preparat koji se koristi u vidu tableta ili rastvora. Tabletu je potrebno izmrviti i pomešati sa 30 ml tečnosti (vode, mleka ili formule). Rastvor se detetu daje preko šprica ili pipete, ne treba ga mešati u celokupni obrok u flašici jer se može desiti da beba ne pojede čitav obrok i da se ne unese potpuna doza leka. Tokom hormonske terapije neophodno je pratiti stanje deteta, jer usled predoziranja levotiroksinom mogu se razviti simptomi hipertireoze: nemir, blage dijareje, sporo napredovanje u telesnoj težini, nesanica, ubrzan rast.

Usled nedovoljne terapijske doze kod deteta se mogu razviti letargija, opstipacija, hladni ekstremiteti, neočekivano dobijanje u telesnoj težini i usporen rast.

Nakon započinjanja hormonske terapije neophodno je pratiti vrednosti tireoidnih hormona. U prvim mesecima hormonski status se proverava svakih par nedelja, odnosno na svakih tri do šest meseci tokom detinjstva, odnosno na svakih 6 do 12 meseci u adultnom dobu [12]. Veliki broj zemalja uvrstio je i hipotireozu u svoj program novorođenačkog skrininga i to na taj način što se iz istog uzorka krvi sa filter papira koji se uzima radi traganja za fenilketonurijom određuje radioimunološki T4 ili TSH.

Novorođenački skrining na galaktozemiju

Zbog nedostatka galaktoza-1-fosfo-uridil-transferaze nastaje klasična galaktozemija [13]. Usled neaktivnosti ove transferaze, dolazi do nagomilavanja galaktozo-1-fosfata u jetri, eritrocitima, slezini, očnom sočivu, bubrezima, srčanom mišiću i moždanoj kori, a u krvi postoji

newborn screening for hypothyroidism as a mandatory form of child health care.

In Montenegro, screening for hypothyroidism was introduced as a mandatory form of child health care in 2008. To date, congenital hypothyroidism is the only endocrine disease included in the newborn screening program.

The main clinical features of untreated congenital hypothyroidism are growth failure and delayed neurocognitive development resulting in mental retardation.

Figure 2. Clinical picture of congenital hypothyroidism
https://www.researchgate.net/publication/44662677/figure/fig4/AS:279090520182836@1443551773718/Infant-with-congenital-hypothyroidism-A-3-month-old-infant-with-untreated-CH-picture_Q320.jpg



Worldwide, the incidence rate of congenital hypothyroidism is 1: 2000-4000 newborns, while areas that are deficient in iodine record a higher incidence rate [10]. Congenital hypothyroidism is diagnosed at birth using the Guthrie test. This test is based on measuring the value of TSH or T4 (thyroxine). If the level of T4 in the blood from the heel prick is low and the TSH is elevated, the screening results indicate the development of congenital hypothyroidism. Confirmation of the diagnosis is made by analyzing hormones from venous blood, where the level of TSH and T4 is also measured. If the value of T4 hormone is low, and the value of TSH is elevated, the diagnosis is confirmed [11].

The goal of hormone replacement therapy is to bring the child to a state of euthyroidism. In diagnosed congenital hypothyroidism, therapy is started with a full dose of hormones in order to prevent or reduce the harmful effects of hypothyroidism on the development of the central nervous system. It is recommended to maintain the concentration of T3 and T4 at the upper limit of normal. At the beginning of the therapy, the level of T4 and T3 is normalized and the elevated TSH is suppressed. With well-managed therapy, normal growth is achieved and clinical signs of hypothyroidism disappear, but the prognosis of mental development is not so favorable and depends above all on the time when the therapy was started. Levothyroxine is a hormonal preparation that is used in the form of tablets or solutions. The tablet should be crushed and mixed with 30 ml of liquid (water, milk or formula). The solution is given to the child through a syringe or pipette, it should not be mixed with the entire meal in the bottle because it may happen that the baby does not eat the entire meal and the full dose of the medicine is not taken. During hormone therapy, it is necessary to monitor the condition of the child, because due to an overdose with levothyroxine, symptoms of hyperthyroidism may develop: restlessness, mild diarrhea, slow progress in body weight, insomnia, accelerated growth.

Due to an insufficient therapeutic dose, the child may develop lethargy, constipation, cold extremities, unexpected weight gain, and slow growth.

After starting hormone therapy, it is necessary to monitor the values of thyroid hormones. In the first months, the hormonal

galaktozemija. Sem intracelularnog nagomilavanja galaktoze i galaktozo-1-fosfata nalazi se i veća količina galaktitola. Nakon nekoliko dana hranjenja majčinim mlekom ili mlečnom formulom koja sadrži laktozu novorođenče postaje anoreksično i požuti. Novorođenče sa klasičnom galaktozemijom često odbija hranu, ne napreduje ili gubi na telesnoj masi, povraća nakon obroka, ima proliv, žuticu, ascites, edeme, hepatomegaliju, letargična je i hipotonična. Oštećenje jetre može napredovati do fulminantog zatajenja s encefalopatijom i hemoragijskom dijatezom, a moguće je zatajenje bubrega [14].

Slika 3. Dete oboljelo od galaktozemije
Izvor: https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcTpVTHhntyHltIfN9_IwAGV4X8QUKZkDzQ51mKrGQqKsz5XitFfyvnvkKHrwiQSg4ZNKxA&usqp=CAU



Deca ostaju niskog rasta uz govorne nedostatke kao i poremećaj držanja tela i ravnoteže tokom adolescencije. Nagomilavanje galaktoze i galaktitola u očnom sočivu dovodi do brzog formiranja katarakte, zamućenja očnog sočiva i gubitka vida. Bolest može biti praćena osteomalacijom, privremenim zatajanjem jajnika, dok teži oblici galaktozemije su praćeni gubitkom sluha [15]. Lečenje galaktozemije se zasniva na dijeti bez imalo galaktoze (za dojenčad je to sojino mleko umjesto kravljeg). Nju treba započeti pri prvoj sumnji na ovu bolest, ne čekajući nalaze pretraga. Ako se dijeta započne na vreme, simptomi se mogu postupno i povući. Dugoročna prognoza lečene dece je dobra, iako ih dio može imati blagi zaostatak u rastu, blaže govorne teškoće i druge diskretne mentalne poremećaje. Bolesnici imaju povišene koncentracije galaktoze u serumu i urinu. Žena koja zna da nosi gen za galaktozemiju mora tokom trudnoće potpunosti prestati uzimati hranu koja sadrži galaktozu. Galaktozemija se može u trudnoći sprečiti odgovarajućom dijetom. Ukoliko majka ima visok nivo galaktoze u krvi, ona može prolaziti kroz posteljicu i izazvati kataraktu. Osobe sa ovim poremećajem moraju se odreći galaktoze za celi život [16].

Skrining na glutarnu aciduriju tip I

Glutarna acidurija tip 1 je teški nasledni neurometabolički poremećaj čiji se klinički ishod poboljšao nakon primene programa skrininga novorođenčadi i brzog početka presimptomatskog metaboličkog lečenja. Glutarna acidemia tipa I je protip tzv. cerebralnih organskih acidurija i rezultat je naslednog poremećaja u metabolizmu aminokiselina lizina, hidroksilizina i triptofana, zbog nedostatka mitohondrijskog enzima glutaril-CoA-dehidrogenaze. U bolesnika s manjkom enzima nakupljaju se glutarična a u manjoj meri 3-OH-glutarična i glutakonična kiselina u mozgu [17]. Procenjena prevalencija bolesti se kreće od 1:125,000 do 1:250 novorođenčadi u genetski visokorizičnim populacijama [18]. Nelečena bolest najčešće uzrokuje sliku akutnog oštećenja mozga s teškim distoničko-diskinetičkim poremećajem. Bolest je asiptomatska do dobi od obično pola godine do godinu dana kada se kod deteta u sklopu neke infekcije, imunizacije ili druge stresne situacije razvije tzv. encefalopatična kriza u kojoj stradaju bazalne ganglije.

status is checked every few weeks, ie every three to six months during childhood, or every 6 to 12 months in adulthood [12]. A large number of countries have included hypothyroidism in their newborn screening program, in such a way that from the same filter paper blood sample that is taken to look for phenylketonuria, T4 or TSH is determined radioimmunological.

Newborn screening for galactosemia

Due to lack of galactose-1-phospho-uridyl-transferase, classic galactosemia occurs [13]. Due to the inactivity of this transferase, galactose-1-phosphate accumulates in the liver, erythrocytes, spleen, eye lens, kidneys, heart muscle and cerebral cortex, and there is galactosemia in the blood. Besides the intracellular accumulation of galactose and galactose-1-phosphate, there is also a larger amount of galactitol. After a few days of feeding with mother's milk or milk formula containing lactose, the newborn becomes anorexic and turns yellow. Infants with classic often refuse food, do not progress or lose weight, vomit after meals, have diarrhea, jaundice, ascites, edema, hepatomegaly, are lethargic and hypotonic. Liver damage can progress to fulminant failure with encephalopathy and hemorrhagic diathesis, and renal failure is possible [14].

Figure 3. A child with galactosemia
https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcTpVTHhntyHltIfN9_IwAGV4X8QUKZkDzQ51mKrGQqKsz5XitFfyvnvkKHrwiQSg4ZNKxA&usqp=CAU



Children remain short with speech defects as well as posture and balance disorders during adolescence. Accumulation of galactose and galactitol in the eye lens leads to the rapid formation of cataracts, clouding of the eye lens and loss of vision. The disease can be accompanied by osteomalacia, temporary ovarian failure, while more severe forms of galactosemia are accompanied by hearing loss [15]. The treatment of galactosemia is based on a diet without any galactose (for infants it is soy milk instead of cow's milk). It should be started at the first suspicion of this disease, without waiting for the test results. If the diet is started in time, the symptoms can gradually disappear. The long-term prognosis of treated children is good, although some of them may have a slight delay in growth, mild speech difficulties and other discrete mental disorders. Patients have elevated concentrations of galactose in serum and urine. A woman who knows she carries the gene for galactosemia must also completely stop eating foods containing galactose during pregnancy. Galactosemia can be prevented during pregnancy with an appropriate diet. If the mother has a high level of galactose in her blood, it can pass through the placenta and cause cataracts. People with this disorder must give up galactose for life [16].

Screening for glutaric aciduria type I

Glutaric aciduria type 1 is a severe inherited neurometabolic disorder whose clinical outcome has improved after the implementation of a newborn screening program and prompt initiation of presymptomatic metabolic treatment.

Glutaric acidemia type I is the antitype of the so-called cerebral organic aciduria and is the result of a hereditary disorder in the metabolism of the amino acids lysine, hydroxylysine and tryptophan, due to the lack of the mitochondrial enzyme glutaryl-CoA-

Slika 4. Dete sa glutarnom acidurijom tip I
Izvor:https://upload.wikimedia.org/wikipedia/commons/thumb/1/19/GA1_posture2.jpg/220px-GA1_posture2.jpg

Bolest se karakteriše neurorazvojnim poremećajima, uključujući: kašnjenje ili deficit u razvoju govora, poteškoće u učenju, poremećaj u intelektualnom razvoju, epilepsiju, makrocefaliju [19]. Kombinovana metabolička terapija uključuje ishranu sa niskim sadržajem lizina, suplementaciju karnitinom i hitno lečenje sa ciljem sprečavanja katabolizma i minimiziranja izloženosti CNS-a lizinu i njegovim toksičnim metaboličkim nusproizvodima [20].

Skrining na cističnu fibrozu

Neonatalni skrining za cističnu fibrozu je optimizovao prognozu za pacijente omogućavajući veoma ranu multidisciplinarnu negu. Tokom proteklih 20 godina, programi skrininga su doživeli veliku međunarodnu ekspanziju. Polovinom 20 veka, kada je bolest otkrivena, deca oboljela od cistične fibroze umirala su tokom prve godine života. Ranom dijagnostikom, poboljšanim lečenjem i primenom novih lekova, prosečni životni vek obolelih je 40 godina. U zemljama koje su uvele neonatalni skrinig, životni vek obolelih je značajno produžen, poboljšan je kvalitet života obolelih i njihovih porodica.

Cistična fibroza je autozomno recesivna bolest koju karakteriše insuficijencija pankreasa i hronična endobronhijalna infekcija disajnih puteva. Hronična infekcija disajnih puteva dovodi do progresivnih bronhiektazija i konačno respiratorne insuficijencije, što je vodeći uzrok smrti kod pacijenata sa cističnom fibrozom. Ostale komplikacije uključuju sinusitis, dijabetes melitus, opstrukciju creva, hepatobilijarnu bolest, hiponatremijsku dehidraciju i neplodnost [21]. Prednost ranog postavljanja dijagnoze cistične fibroze neonatalnim skriningom je višestruka: primena preventivnih i ranih terapijskih intervencija, redovno kontrolisanje i rano otkrivanje komplikacija, značajno bolje preživljavanje obolelih, duži i kvalitetniji život obolelih, sporija progresija plućne bolesti, prevencija malnutricije, bolja uhranjenost, omogućavanje normalnog rasta i razvoja dece.

ZAKLJUČAK

Dijagnostikovanje bolesti u najranijoj životnoj dobi omogućava brzi terapijski pristup, koji dovodi do normalnog psihofizičkog rasta i razvoja deteta i prevenira trajna telesna i intelektualna oštećenja. Nasledne metaboličke i endokrinološke bolesti se karakterišu visokim procentom telesnog i mentalnog invaliditeta, koji pogađa ne samo zdravlje i socijalno funkcionisanje deteta već i celu porodicu, zajednicu i društvo. Skrining na kongenitalnu hipotireozu se počeo primenjivati u Crnoj Gori u 2007. godini. To je jedino endokrinološko obolenje koje je predmet novorođenačkog skrininga u Crnoj Gori.

LITERATURA

1. Advisory Committe on Heritable Disorders in Newborn and children; Recommended Uniform Screening Panel. [Internet] [Citirano 2021 Novembar 02]. Dostupno na: https://ww.hrsa.gov/advisory-committes/heritable dosorders/rusp/index.html
2. Stone WL, Basit H, Los E. Phenylketonuria. 2021 Nov 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. [Citirano 2022 Avgust 01]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/30570999/
3. Woolf LI, Adams J. The Early History of PKU. Int J Neonatal Screen. 2020;6(3):59. [Citirano 2022 Jul 28]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/33239585/
4. Mancilla VJ, Mann AE, Zhang Y, Allen MS. The Adult Phenylketonuria (PKU) Gut Microbiome. Microorganisms. 2021;9(3):530. [Citirano 2022 Avgust

dehydrogenase. In patients with enzyme deficiency, glutaric and, to a lesser extent, 3-OH-glutaric and glutaconic acid accumulate in the brain [17]. The estimated prevalence of the disease ranges from 1:125,000 to 1:250 newborns in genetically high-risk populations [18]. Untreated disease most often causes a picture of acute brain damage with severe dystonic-dyskinetic disorder (Figure 6). The disease is asymptomatic until the age of usually half a year to a year, when the child develops the so-called. encephalopathic crisis in which the basal ganglia are affected.

Figure 4. Child with glutaric aciduria type Ⅰ
https://upload.wikimedia.org/wikipedia/commons/thumb/1/19/GA1_posture2.jpg/220px-GA1_posture2.jpg

The disease is characterized by neurodevelopmental disorders, including: delay/deficit in speech development, learning difficulties, intellectual development disorder, epilepsy, macrocephaly [19]. Combined metabolic therapy includes a low-lysine diet, carnitine supplementation, and emergency treatment during the episode to prevent catabolism and minimize CNS exposure to lysine and its toxic metabolic byproducts [20].

Screening for cystic fibrosis

Neonatal screening for cystic fibrosis has optimized patient prognosis by enabling very early multidisciplinary care. Over the past 20 years, screening programs have experienced a major international expansion. Cystic fibrosis is included in the screening program in Serbia. In the middle of the 20th century, when the disease was discovered, children suffering from cystic fibrosis died within the first year of life. With early diagnosis, improved treatment and the use of new drugs, the average life expectancy of sufferers is 40 years. In countries that have introduced neonatal screening, the life expectancy of patients has been significantly extended, and the quality of life of patients and their families has improved.

Cystic fibrosis is an autosomal recessive disease characterized by pancreatic insufficiency and chronic endobronchial infection of the respiratory tract. Chronic airway infection leads to progressive bronchiectasis and ultimately respiratory failure, which is the leading cause of death in patients with cystic fibrosis. Other complications include sinusitis, diabetes mellitus, intestinal obstruction, hepatobiliary disease, hyponatremic dehydration, and infertility [21].

The advantage of early diagnosis of cystic fibrosis through neonatal screening is multiple: application of preventive and early therapeutic interventions, regular control and early detection of complications, significantly better survival of patients, longer and better quality of life of patients, slower progression of lung disease, prevention of malnutrition, better nutrition, normal growth and child development.

CONCLUSION

Detection of the disease at the earliest age enables a quick therapeutic approach, thus ensuring adequate psychophysical growth and development of the child and preventing permanent physical and intellectual deficits. Hereditary metabolic and endocrinological diseases are characterized by a high percentage of physical and mental disability, which affects not only the health and social functioning of the child, but it affects the whole family, community and society. Screening for congenital hypothyroidism began in Montenegro in 2007. It is the only endocrinological hereditary disorder

04]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/33806544/
5. Wiedemann A, Oussalah A, Jeannesson É, Guéant JL, Feillet F. La phénylcétonurie - De la diététique à la thérapie génique [Phenylketonuria, from diet to gene therapy]. Med Sci (Paris). 2020;36(8-9):725-734. [Citirano 2022 Avgust 04]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/32821049/
6. van Spronsen FJ, Blau N, Harding C, Burlina A, Longo N, Bosch AM. Phenylketonuria. Nat Rev Dis Primers. 202;7(1):36. [Citirano 2022 Avgust 04]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/34017006/
7. Chen S, Zhu M, Hao Y, Feng J, Zhang Y. Effect of Delayed Diagnosis of Phenylketonuria With Imaging Findings of Bilateral Diffuse Symmetric White Matter Lesions: A Case Report and Literature Review. Front Neurol. 2019;10:1040. [Citirano 2022 Avgust 04]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/31636599/
8. MacDonald A, van Wegberg AMJ, Ahring K, Beblo S, Bélanger-Quintana A, Burlinaet et al., APKU dietary handbook to accompany PKU guidelines. Orphanet J Rare Dis. 2020;15(1):171. [Citirano 2022 Avgust 05]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/32605583/
9. Arduini GAO, Balarin MAS, Silva-Grecco RLD, Marqui ABT. KNOWLEDGE OF PUERPERAL MOTHERS ABOUT THE GUTHRIE TEST. Rev Paul Pediatr. 2017;35(2):151-157. [Citirano 2022 Avgust 05]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/28977324/
10. Guerri G, Bressan S, Sartori M, Costantini A, Benedetti S, Agostini F et al., Hypothyroidism and hyperthyroidism. Acta Biomed. 2019;90(10-S):83-86. [Citirano 2022 Avgust 05]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/31577260/
11. American thyroid association (2020). A review of the 2020 guidlines for congenital hypothyroidism. [Citirano 2021 Novembar 03] Dostupno na: http://www.thyroid.org/congenital-hypothyroidism/
12. British Thyroid foundation (2018). Congenital hypothyroidism. [Citirano 2021 Novembar 02] Dostupno na :www.british-thyroid-association.org
13. Yuzyuk T, Balakrishnan B, Schwarz EL, De Biase I, Hobert J, Longo N et al., Effect of genotype on galactose-1-phosphate in classic galactosemia patients. Mol Genet Metab. 2018;125(3):258-265. [Citirano 2022 Avgust 05]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/30172461/
14. Lak R, Yazdizadeh B, Davari M, Nouhi M, Kelishadi R. Newborn screening for galactosaemia. Cochrane Database Syst Rev. 2017;12(12):CD012272. [Citirano 2022 Avgust 05]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/29274129/
15. Hrvatski liječnički zbor u saradnji sa farmaceutskom tvrtkom MSD (2014) MSD priručnik dijagnostike i terapije. [Citirano 2022 Januar 06]. Dostupno na: http://www.msd-prirucnici.placebo.hr/msd-prirucnik/pedijatrija/nasljedne-metaboličke-bolesti/galaktozemija
16. Kiss E, Balogh L, Reismann P. Klasszikus galactosaemia dietetikai kezelési lehetőségei [Diet treatment of classical galactosemia]. Orv Hetil. 2017;158(47):1864-1867. Hungarian. [Citirano 2022 Avgust 05]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/29153024/
17. Boy N, Mohr A, Garbade SF, Freisinger P, Heringer-Seifert J, Seitz A et al., Subdural hematoma in glutaric aciduria type 1: High excreters are prone to incidental SDH despite newborn screening. J Inherit Metab Dis. 2021;44(6):1343-1352. [Citirano 2022 Avgust 05]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/34515344/
18. Boy N, Mengler K, Heringer-Seifert J, Hoffmann GF, Garbade SF, Kölker S. Impact of newborn screening and quality of therapy on the neurological outcome in glutaric aciduria type 1: a meta-analysis. Genet Med. 2021;23(1):13-21. doi: 10.1038/s41436-020-00971-4. Epub 2020 Sep 28. PMID: 32981931; PMCID: PMC7790745.
19. Pokora P, Jezela-Stanek A, Różdżyńska-Świątkowska A, Jurkiewicz E, Bogdańska A, Szymańska E, Rokicki D, Ciara E, Rydzanicz M, Stawiński P, Płoski R, Tylki-Szymańska A. Mild phenotype of glutaric aciduria type 1 in polish patients - novel data from a group of 13 cases. Metab Brain Dis. 2019;34(2):641-649. doi: 10.1007/s11011-018-0357-5. Epub 2018 Dec 20. PMID: 30570710; PMCID: PMC6428789.
20. Larson A, Goodman S. Glutaric Acidemia Type 1.. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 2019;1993–2022. PMID: 31536184.
21. Goetz D, Ren CL. Review of Cystic Fibrosis. Pediatr Ann. 2019;48(4):e154-e161. doi: 10.3928/19382359-20190327-01. PMID: 30986316.

that is included in the screening program in Montenegro. From the surrounding countries Croatia has the largest number of diseases included in the screening program, eight diseases: phenylketonuria, hypothyroidism, three fatty acid breakdown disorders, glutaric aciduria type 1, isovaleric aciduria, carnitine carrier deficiency.

REFERENCES

1. Advisory Committe on Heritable Disorders in Newborn and children; Recommended Uniform Screening Panel. [Internet] [Citirano 2021 Novembar 02]. Dostupno na: https://ww.hrsa.gov/advisory-committes/heritable dosorders/rusp/index.html
2. Stone WL, Basit H, Los E. Phenylketonuria. 2021 Nov 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. [Citirano 2022 Avgust 01]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/30570999/
3. Woolf LI, Adams J. The Early History of PKU. Int J Neonatal Screen. 2020;6(3):59. [Citirano 2022 Jul 28]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/33239585/
4. Mancilla VJ, Mann AE, Zhang Y, Allen MS. The Adult Phenylketonuria (PKU) Gut Microbiome. Microorganisms. 2021;9(3):530. [Citirano 2022 Avgust 04]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/33806544/
5. Wiedemann A, Oussalah A, Jeannesson É, Guéant JL, Feillet F. La phénylcétonurie - De la diététique à la thérapie génique [Phenylketonuria, from diet to gene therapy]. Med Sci (Paris). 2020;36(8-9):725-734. [Citirano 2022 Avgust 04]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/32821049/
6. van Spronsen FJ, Blau N, Harding C, Burlina A, Longo N, Bosch AM. Phenylketonuria. Nat Rev Dis Primers. 202;7(1):36. [Citirano 2022 Avgust 04]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/34017006/
7. Chen S, Zhu M, Hao Y, Feng J, Zhang Y. Effect of Delayed Diagnosis of Phenylketonuria With Imaging Findings of Bilateral Diffuse Symmetric White Matter Lesions: A Case Report and Literature Review. Front Neurol. 2019;10:1040. [Citirano 2022 Avgust 04]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/31636599/
8. MacDonald A, van Wegberg AMJ, Ahring K, Beblo S, Bélanger-Quintana A, Burlinaet et al., APKU dietary handbook to accompany PKU guidelines. Orphanet J Rare Dis. 2020;15(1):171. [Citirano 2022 Avgust 05]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/32605583/
9. Arduini GAO, Balarin MAS, Silva-Grecco RLD, Marqui ABT. KNOWLEDGE OF PUERPERAL MOTHERS ABOUT THE GUTHRIE TEST. Rev Paul Pediatr. 2017;35(2):151-157. [Citirano 2022 Avgust 05]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/28977324/
10. Guerri G, Bressan S, Sartori M, Costantini A, Benedetti S, Agostini F et al., Hypothyroidism and hyperthyroidism. Acta Biomed. 2019;90(10-S):83-86. [Citirano 2022 Avgust 05]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/31577260/
11. American thyroid association (2020). A review of the 2020 guidlines for congenital hypothyroidism. [Citirano 2021 Novembar 03] Dostupno na: thyroid.org/congenital-hypothyroidism
12. British Thyroid foundation (2018). Congenital hypothyroidism. [Citirano 2021 Novembar 02] Dostupno na :www.british-thyroid-association.org
13. Yuzyuk T, Balakrishnan B, Schwarz EL, De Biase I, Hobert J, Longo N et al., Effect of genotype on galactose-1-phosphate in classic galactosemia patients. Mol Genet Metab. 2018 Nov;125(3):258-265. [Citirano 2022 Avgust 05]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/30172461/
14. Lak R, Yazdizadeh B, Davari M, Nouhi M, Kelishadi R. Newborn screening for galactosaemia. Cochrane Database Syst Rev. 2017;12(12):CD012272. [Citirano 2022 Avgust 05]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/29274129/
15. Hrvatski liječnički zbor u saradnji sa farmaceutskom tvrtkom MSD (2014) MSD priručnik dijagnostike i terapije. [Citirano 2022 Januar 06]. Dostupno na: http://www.msd-prirucnici.placebo.hr/msd-prirucnik/pedijatrija/nasljedne-metaboličke-bolesti/galaktozemija
16. Kiss E, Balogh L, Reismann P. Klasszikus galactosaemia dietetikai kezelési lehetőségei [Diet treatment of classical galactosemia]. Orv Hetil. 2017;158(47):1864-1867. Hungarian. [Citirano 2022 Avgust 05]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/29153024/
17. Boy N, Mohr A, Garbade SF, Freisinger P, Heringer-Seifert J, Seitz A et al., Subdural hematoma in glutaric aciduria type 1: High excreters are prone to incidental SDH despite newborn screening. J Inherit Metab Dis. 2021;44(6):1343-1352. [Citirano 2022 Avgust 05]. Dostupno na: https://pubmed.ncbi.nlm.nih.gov/34515344/
18. Boy N, Mengler K, Heringer-Seifert J, Hoffmann GF, Garbade SF, Kölker S. Impact of newborn screening and quality of therapy on the neurological outcome in glutaric aciduria type 1: a meta-analysis. Genet Med. 2021;23(1):13-21. doi: 10.1038/s41436-020-00971-4. Epub 2020 Sep 28. PMID: 32981931; PMCID: PMC7790745.
19. Pokora P, Jezela-Stanek A, Różdżyńska-Świątkowska A, Jurkiewicz E, Bogdańska A, Szymańska E, Rokicki D, Ciara E, Rydzanicz M, Stawiński P, Płoski R, Tylki-Szymańska A. Mild phenotype of glutaric aciduria type 1 in polish patients - novel data from a group of 13 cases. Metab Brain Dis. 2019;34(2):641-649. doi: 10.1007/s11011-018-0357-5. Epub 2018 Dec 20. PMID: 30570710; PMCID: PMC6428789.
20. Larson A, Goodman S. Glutaric Acidemia Type 1.. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 2019;1993–2022. PMID: 31536184.
21. Goetz D, Ren CL. Review of Cystic Fibrosis. Pediatr Ann. 2019;48(4):e154-e161. doi: 10.3928/19382359-20190327-01. PMID: 30986316.